Fig. 3

Quantification of anti-HCV double-drug combinations against genotype 1b and 2a: Log–log plots of dose-response curves for 43 (a) and 9 (b) double-drug combinations of inter-class (or subclass) antiviral drugs against genotype 1b (a) and genotype 2a (b). Each point represents the mean of four experiments. For comparison of drugs, concentration of each drug was based on a consistent ratio of its IC₅₀ value. (c) Dose-response curve for a hypothetical double-drug combination. RCI₉₅ for (double or triple-) drug combinations can be determined from the point where the curve intersects \( {f}_u^{\mathrm{com}}=0.05 \) (dashed line). (d) and (e) show RCI₉₅ rankings for 43 double-combinations against HCV genotype 1b and 9 double-combinations against HCV genotype 2a, respectively. Combinations with gray bars and black numbers (e.g., ❶) correspond to treatment regimens that include HTAs. Light pink to blue bars and white numbers (e.g., ②) correspond to treatment combinations with DAA-only